Evidence-based interventions for reducing sickle cell disease-associated morbidity and mortality in sub-Saharan Africa: A scoping review
- PMID: 37719166
- PMCID: PMC10504846
- DOI: 10.1177/20503121231197866
Evidence-based interventions for reducing sickle cell disease-associated morbidity and mortality in sub-Saharan Africa: A scoping review
Abstract
Objective: Sickle cell disease is a lifelong illness affecting millions of people globally, but predominantly burdensome in sub-Saharan Africa, where most affected children do not live to adulthood, despite available evidence-based interventions that reduce the disease burden in high-income countries.
Method: We reviewed studies evaluating evidence-based interventions that decrease sickle cell disease-related morbidity and mortality among children living in sub-Saharan Africa. We used the Joanna Briggs scoping review methodological framework and grouped identified evidence-based interventions into preventative pharmacotherapeutic agents, newborn screening and comprehensive healthcare, disease-modifying agents, nutritional supplementation, systemic treatment, supportive agents and patient/carer/population education.
Results: We included 36 studies: 18 randomized controlled trials, 11 observational studies, 5 before-and-after studies and 2 economic evaluation studies, with most of the studies performed in West African countries. Included studies suggest evidence-based interventions effectively to reduce the common morbidities associated with sickle cell disease such as stroke, vaso-occlusive crisis, acute chest syndrome, severe anaemia and malaria infection. Evidence-based interventions also improve survival among study participants. Specifically, our review shows hydroxyurea increases haemoglobin and foetal haemoglobin levels, a finding with practical implications given the challenges with blood transfusion in this setting. The feasibility of implementing individual interventions is hampered by challenges such as affordability, accessibility and the availability of financial and human resources.
Conclusion: Our review suggests that regular use of low-dose hydroxyurea therapy, sulphadoxine-pyrimethamine chemoprophylaxis, L-arginine and Omega-3 fatty acid supplementation and establishment of specialist stand-alone sickle cell clinics could reduce the sickle cell disease-associated morbidity and mortality in sub-Saharan Africa countries.
Keywords: evidence-based medicine; scoping review; sickle cell disease; sub-Saharan Africa.
© The Author(s) 2023.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.Pharmacotherapy. 2023 May;43(5):430-441. doi: 10.1002/phar.2792. Epub 2023 Mar 26. Pharmacotherapy. 2023. PMID: 36906823 Review.
-
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.N Engl J Med. 2019 Jan 10;380(2):121-131. doi: 10.1056/NEJMoa1813598. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501550 Free PMC article. Clinical Trial.
-
A Critical Review of Sickle Cell Disease Burden and Challenges in Sub-Saharan Africa.J Blood Med. 2023 May 31;14:367-376. doi: 10.2147/JBM.S406196. eCollection 2023. J Blood Med. 2023. PMID: 37284610 Free PMC article. Review.
-
Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study.Lancet Haematol. 2022 Mar;9(3):e208-e216. doi: 10.1016/S2352-3026(22)00004-7. Lancet Haematol. 2022. PMID: 35240076
-
Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care.Lancet Haematol. 2021 Oct;8(10):e744-e755. doi: 10.1016/S2352-3026(21)00191-5. Epub 2021 Sep 2. Lancet Haematol. 2021. PMID: 34481550 Review.
Cited by
-
Evolving Landscape of Sickle Cell Anemia Management in Africa: A Critical Review.Trop Med Infect Dis. 2024 Nov 29;9(12):292. doi: 10.3390/tropicalmed9120292. Trop Med Infect Dis. 2024. PMID: 39728819 Free PMC article. Review.
-
Distribution of Silent Cerebral Infarcts in Adults With Sickle Cell Disease.Neurology. 2024 May;102(10):e209247. doi: 10.1212/WNL.0000000000209247. Epub 2024 Apr 29. Neurology. 2024. PMID: 38684044 Free PMC article.
-
Genetic Patterns of Oral Cavity Microbiome in Patients with Sickle Cell Disease.Int J Mol Sci. 2024 Aug 6;25(16):8570. doi: 10.3390/ijms25168570. Int J Mol Sci. 2024. PMID: 39201258 Free PMC article.
-
Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions.Nutrients. 2024 Jan 15;16(2):258. doi: 10.3390/nu16020258. Nutrients. 2024. PMID: 38257151 Free PMC article. Review.
References
-
- Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. Lancet 2017; 6736: 30193–30199. - PubMed
Publication types
LinkOut - more resources
Full Text Sources